The Potential Use of the Plasma Biomarker CXCL9 (MIG), Interleukin 2 Receptor alpha (IL2Rα) and SCGF-b as Predictors of Renal Graft Rejection
1Technical Chemistry, Leibniz University, Hannover, Germany
2Musculo Sceletal Reserach, University of Wuerzburg, Wuerzburg, Germany
3Transplant Immunology, Medical School Hannover, Hannover, Germany
4Dept. Nephrology, Medical School Hannover, Hannover, Germany.
Meeting: 2015 American Transplant Congress
Abstract number: C278
Keywords: Area-under-curve (AUC), Prediction models, Rejection
Session Information
Session Name: Poster Session C: Translational Biomarkers and Immune Monitoring
Session Type: Poster Session
Date: Monday, May 4, 2015
Session Time: 5:30pm-6:30pm
Presentation Time: 5:30pm-6:30pm
Location: Exhibit Hall E
Background: Early detection of rejection in kidney transplantation is crucial, and predictive plasma biomarkers are highly desirable as non-invasive tests.
Methods: From a cohort of 120 kidney transplant recipients (KTRs) participating in a routine biopsy program, plasma and selected biopsy probes taken were screened for 56 cytokines, chemokines, and growth factors as possible indicators of several types of rejection as manifest T-cell mediated rejection (TCMR) and TCMR categorized as borderline changes or antibody mediated rejection (AMR). Categorization was performed according zo the current Banff Classification. Receiver-operating characteristic curves (ROC-analysis) selected three biomarkers with sufficient diagnostic accuracy. The diagnostic performance for any type of rejection was investigated for each biomarker alone or in combinations with serum creatinine.
Results: High CXCL9 (MIG), high IL2Rα and low SCGF-b levels were characterized as reliable indicators of rejection with high specificity. Combination of these markers with serum creatinine could prevent up to 22 % of all biopsies performed in this study.
Conclusions: CXCL9 (MIG) as a T-cell chemoattractant and IL2Rα as a marker for T-cell activation were associated with rejection, whereas SCGF-b as an activator of endothelial progenitor cells correlated to non-rejection reflects high regenerative graft activity. The use of these markers would also be helpful in transplant outpatient centers without the possibility to perform protocol biopsies.
To cite this abstract in AMA style:
Blume C, Michael S, Christine N, Hermann H, Christine F. The Potential Use of the Plasma Biomarker CXCL9 (MIG), Interleukin 2 Receptor alpha (IL2Rα) and SCGF-b as Predictors of Renal Graft Rejection [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/the-potential-use-of-the-plasma-biomarker-cxcl9-mig-interleukin-2-receptor-alpha-il2r-and-scgf-b-as-predictors-of-renal-graft-rejection/. Accessed May 16, 2025.« Back to 2015 American Transplant Congress